$XERS News

Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings

Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit

Xeris Biopharma Q1 Earnings Call Highlights

Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call Summary

Xeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's Changed

Xeris (XERS) Q1 2026 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript

Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge

Xeris Biopharma Reports First Quarter 2026 Financial Results

Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $375.000M-$390.000M to $380.000M-$390.000M vs $383.864M Est

Xeris Biopharma Holdings Q1 EPS $0.01 Beats $(0.00) Estimate, Sales $83.127M Beat $79.992M Estimate

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

Does Record Q4 Results, Robust 2026 Guidance and Recorlev Patent Suit Change The Bull Case For Xeris (XERS)?

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio

Xeris Biopharma Balances New Profitability With Recorlev Patent Battles

Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...

Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary